Analysts expect Vical Incorporated (NASDAQ:VICL) to report earnings per share of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Vical’s earnings, with estimates ranging from ($0.23) to ($0.21). Vical reported earnings per share of ($0.27) during the same quarter last year, which would suggest a positive year over year growth rate of 18.5%. The company is expected to report its next earnings results on Monday, October 22nd.

On average, analysts expect that Vical will report full-year earnings of ($0.95) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.92). For the next year, analysts expect that the company will post earnings of ($1.02) per share. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Vical.

Vical (NASDAQ:VICL) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. The company had revenue of $0.74 million during the quarter, compared to analyst estimates of $0.51 million.

A number of equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Vical from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a report on Friday, August 10th. HC Wainwright set a $4.00 price target on shares of Vical and gave the company a “buy” rating in a report on Wednesday, August 8th.

Hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Vical in the 2nd quarter worth $205,000. Renaissance Technologies LLC raised its holdings in Vical by 13.9% in the 2nd quarter. Renaissance Technologies LLC now owns 877,729 shares of the biotechnology company’s stock worth $1,009,000 after purchasing an additional 107,100 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Vical by 20.0% in the 2nd quarter. BlackRock Inc. now owns 394,320 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 65,732 shares in the last quarter. Institutional investors and hedge funds own 45.78% of the company’s stock.

NASDAQ:VICL opened at $1.44 on Friday. Vical has a 52 week low of $1.02 and a 52 week high of $3.70.

Vical Company Profile

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection.

See Also: Do Tariffs Work?

Get a free copy of the Zacks research report on Vical (VICL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.